Industry
Biotechnology
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
February 29, 2024 | 11:32 am
Portfolio Pulse from Benzinga Newsdesk
February 22, 2024 | 11:37 am
Portfolio Pulse from Benzinga Insights
February 22, 2024 | 10:27 am
Portfolio Pulse from Benzinga Insights
February 21, 2024 | 7:02 pm
Portfolio Pulse from Erica Kollmann
January 05, 2024 | 5:03 pm
Portfolio Pulse from ryanfaloona@benzinga.com
January 05, 2024 | 1:53 pm
Portfolio Pulse from Benzinga Insights
January 05, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
November 21, 2023 | 11:32 am
Portfolio Pulse from Benzinga Insights
November 14, 2023 | 1:23 pm
Portfolio Pulse from Benzinga Insights
November 14, 2023 | 11:35 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.